Skip to main content
All inhalers

SPIRIVA RESPIMAT

Tiotropium

SPIRIVA RESPIMAT

LAMA SMI

Tiotropium bromide · Boehringer Ingelheim

Clinical Reference

Active Medication & Mechanism

  • Tiotropium bromide monohydrate LAMA
    1.25 mcg or 2.5 mcg per actuation

    Long-acting muscarinic antagonist. Provides 24-hour bronchodilation by blocking M3 muscarinic receptors on airway smooth muscle with very slow receptor dissociation kinetics.

FDA-Approved Dosing by Indication

// approval varies by strength + age
Asthma
1/2 approved regimens
StrengthPopulationDose & FrequencyTotal DailyStatus
1.25 mcgPatients ≥6 years2 puffs (2.5 mcg total) once daily
Add-on maintenance treatment of asthma in patients ≥6 years already on ICS. Not a substitute for ICS.
2.5 mcg FDA Approved
Any strengthAcute bronchospasm Not Approved
Not a rescue inhaler. Use a SABA for acute symptoms.
COPD
1/2 approved regimens
StrengthPopulationDose & FrequencyTotal DailyStatus
2.5 mcgAdults (≥18 years)2 puffs (5 mcg total) once daily
Long-term, once-daily maintenance treatment of bronchospasm in COPD. Also reduces exacerbations.
5 mcg FDA Approved
1.25 mcgAdults (≥18 years) Not Approved
The 1.25 mcg strength is NOT indicated for COPD — use the 2.5 mcg strength.
Acute Use
0/1 approved regimens
StrengthPopulationDose & FrequencyTotal DailyStatus
Any strengthAcute bronchospasm / rescue Not Approved
Onset too slow for rescue. Use a SABA.

For clinical reference only. This workspace is intended for use by qualified healthcare professionals and is not a substitute for clinical judgement, prescribing information, or product monographs. Always verify doses and indications against the most current labelling before prescribing.

Inhaler Database · © inhalerdatabase.com 2024–2026 — All rights reserved